Corcept Therapeutics
Develops cortisol-modulating medicines for endocrine disease and cancer.
$115.08
After-hours close+1.21 (+1.06%)
At close$113.87(−2.62%)
Something off on this page? Send us feedback.
Breakdown13F · Form 4
Institutions 86.06%93.03M sharesInsiders 6.69%7.23M sharesOther 7.25%7.84M shares
Shares outstanding 108.10M · Float 90.57M · 83.8% free float
Institutions13F, as of Jun 30, 2026
450 holders · 93.03M shares · 131 new positions · 280 increased · 110 reduced · 53 closed
| Holder | Shares | % outstanding | Chg q/q | Filed |
|---|---|---|---|---|
| BlackRock, Inc. | 12.43M | 11.50% | +280.7K | Aug 7, 2026 |
| Ingalls & Snyder LLC | 7.93M | 7.34% | +325.8K | Aug 14, 2026 |
| Renaissance Technologies LLC | 5.26M | 4.87% | −421.2K | Aug 13, 2026 |
| Vanguard Portfolio Management LLC | 5.04M | 4.67% | +224.1K | Aug 13, 2026 |
| Vanguard Capital Management LLC | 4.17M | 3.86% | +95.3K | Aug 13, 2026 |
| Parallel Advisors, LLC | 3.96M | 3.67% | −15.2K | Aug 5, 2026 |
| FMR LLC | 3.34M | 3.09% | +147.4K | Aug 13, 2026 |
| State Street Corp | 3.28M | 3.03% | +78.4K | Aug 7, 2026 |
Beneficial owners13D/G · 5% or more, as filed
| Holder | % of class | Shares | Form | Filed |
|---|---|---|---|---|
| BlackRock, Inc. | 10.90% | 11.54M | 13G | Jul 17, 2025 ↗ |
| Ingalls & Snyder LLC | 7.80% | 8.17M | 13G | Feb 21, 2025 ↗ |
| Joseph K. Belanoff | 6.30% | 6.82M | 13G | Feb 14, 2025 ↗ |
| Renaissance Technologies LLC | 5.47% | 5.76M | 13G | Feb 12, 2026 ↗ |
InsidersForm 4
| Insider | Role | Shares | % outstanding | Filed |
|---|---|---|---|---|
| Joseph K. Belanoff | director, officer: Chief Executive Officer | 2.57M | 2.37% | Jun 2, 2026 |
| G. Leonard Jr Baker | director | 2.11M | 1.95% | Mar 19, 2026 |
| David L. Mahoney | director | 1.13M | 1.05% | Aug 20, 2026 |
| James N. Wilson | director | 1.07M | 0.99% | Aug 18, 2026 |
| Hazel Hunt | officer: Chief Scientific Officer | 255.4K | 0.24% | Feb 11, 2026 |
| Gary Charles Robb | officer: Chief Business Officer | 53.1K | 0.05% | Aug 18, 2026 |
| Atabak Mokari | officer: Chief Financial Officer | 16.1K | 0.01% | Aug 3, 2026 |
| Sean Maduck | officer: See Remarks | 14.9K | 0.01% | Aug 27, 2026 |
| Joseph Douglas Lyon | officer: See Remarks | 5.5K | 0.01% | Aug 5, 2026 |
| William Guyer | officer: Chief Development Officer | 4.0K | 0.00% | Aug 12, 2026 |
17 ten-percent owners hold 33.12M shares by Form 4, outside the officers-and-directors figure above · 11 people have not refiled in the last 18 months (5.59M shares), so they are not in the figure above
Latest trades
| Date | Insider | Type | Shares | Avg price | Owned after |
|---|---|---|---|---|---|
| Aug 26, 2026 | Kimberly Parkdirector | Sale | 26,685 | $122.55 | 0 |
| Aug 25, 2026 | Sean Maduckofficer: See Remarks | Sale · 2 lots | 30,955 | $125.58 | 9,755 |
| Aug 18, 2026 | David L. Mahoneydirector | Sale · 4 lots | 103,606 | $118.25 | 1,133,539 |
| Aug 17, 2026 | Gary Charles Robbofficer: Chief Business Officer | Sale | 10,000 | $116.26 | 39,716 |
| Aug 14, 2026 | James N. Wilsondirector | Sale · 3 lots | 10,000 | $111.43 | 1,074,543 |
| Aug 14, 2026 | Sean Maduckofficer: See Remarks | Sale | 3,664 | $114.49 | 9,755 |
| Aug 10, 2026 | William Guyerofficer: Chief Development Officer | Sale · 2 lots | 16,300 | $113.43 | 3,985 |
| Aug 10, 2026 | Sean Maduckofficer: See Remarks | Sale | 1,031 | $114.52 | 9,755 |
| Aug 4, 2026 | William Guyerofficer: Chief Development Officer | Sale | 3,700 | $113.12 | 3,985 |
| Aug 3, 2026 | Joseph Douglas Lyonofficer: See Remarks | Sale | 1,540 | $114.16 | 5,495 |
CongressHouse and Senate disclosures
Not reported.